Instalab
logoInstalab

Aerobic Vaginitis

Vaginal Swab Test
The often-missed inflammatory vaginal infection that standard bacterial vaginosis testing can quietly overlook.
4.9 (4,562 reviews)
Tested by US Biotek Laboratories
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Aerobic Vaginitis test?

This test is most useful if any of these apply to you.

Stuck With Recurring Symptoms
If you keep getting vaginal burning, irritation, or unusual discharge despite negative standard tests, this can find what's actually going on.
Pregnant or Planning to Be
This infection is linked with serious postpartum complications and premature rupture of membranes, so catching it early matters.
Struggling With Mixed Infections
If you've been treated for bacterial vaginosis or yeast but symptoms keep returning, mixed infections including this one are common and treatable.
Going Through or Past Menopause
Lower estrogen changes vaginal flora and raises your risk of this inflammatory imbalance, even if you've never had vaginal infections before.

About Aerobic Vaginitis

If you have unexplained vaginal burning, yellow or yellow-green discharge, or recurring irritation that keeps coming back after standard treatment, aerobic vaginitis (AV) may be the answer your routine swab missed. It is a distinct, inflammation-driven condition that is often confused with bacterial vaginosis but behaves very differently in your body.

Unlike many common vaginal panels that look only for bacterial vaginosis, Candida, and Trichomonas, this test specifically detects the aerobic bacterial overgrowth pattern that drives AV. Knowing whether AV is present changes which treatment will actually work and which can make things worse.

What This Test Actually Measures

AV (aerobic vaginitis) is not a single molecule but a composite pattern seen on a vaginal swab. It combines four observations: a drop in protective Lactobacillus bacteria, the appearance of oxygen-loving bacteria like Escherichia coli, Klebsiella, Enterococcus, group B Streptococcus, and Staphylococcus aureus, the presence of inflammatory white blood cells, and the appearance of immature surface cells called parabasal cells.

The reference diagnostic method uses a scoring system (the Donders score) on a vaginal smear, where higher scores indicate more severe AV. Many modern labs also use molecular methods (quantitative PCR, a DNA-based bacterial counting technique) to identify the specific aerobic bacteria involved and confirm reduced lactobacilli.

Why It Matters for Pregnancy

In a study of 323 Vietnamese pregnant women, AV in the third trimester was about 8.6 times more likely to be followed by puerperal sepsis (serious infection after delivery) compared to women without AV (odds ratio 8.65, with a wide confidence interval reflecting the small number of events). AV was found in 15.5% of these pregnant women, making it far from rare.

A larger study of 624 women in late pregnancy (part of a broader 989-person cohort that also included nonpregnant controls) found AV was common and associated with premature rupture of membranes. Narrative reviews link AV during pregnancy to premature delivery, stillbirth, and other adverse outcomes, though the exact mechanisms continue to be studied.

The Cervical Cancer Connection

In a study of 622 women, moderate or severe AV and vaginal inflammation were independently associated with an increased risk of major cervical cell abnormalities found on Pap smears. Bacterial vaginosis, by contrast, was not. This is an important distinction because it pushes back on the common assumption that any vaginal dysbiosis carries the same cervical risk.

This isn't a paradox so much as a reminder that vaginal infections are not interchangeable. AV is driven by inflammation and tissue irritation, while bacterial vaginosis is largely non-inflammatory. The inflammation associated with AV appears to be what creates the cellular environment linked with abnormal cervical findings.

Risk Beyond Pregnancy

AV is frequently found in mixed infections alongside bacterial vaginosis and vulvovaginal candidiasis. In a study of 1,674 women, mixed vaginitis in late pregnancy was associated with increased risk of peripartum infection. In fertility settings, broad vaginal dysbiosis (including AV) has been linked to higher early pregnancy loss in women undergoing IVF, though the evidence is not AV-specific.

AV is also notable for antibiotic resistance. In an Ethiopian study of reproductive-age women, roughly 66% of the bacteria causing AV were multidrug-resistant. An Italian retrospective study of 2,069 women found that aerobic vaginitis pathogens showed substantial resistance to penicillins and tetracyclines. This means treating blindly without identifying the specific bacteria can fail.

How AV Differs From Bacterial Vaginosis

FeatureAerobic VaginitisBacterial Vaginosis
InflammationPronounced, with white blood cellsMinimal to none
Typical bacteriaE. coli, Strep, Staph, EnterococcusGardnerella, Prevotella, Atopobium
DischargeYellow to green, thick or mucoid, foul or rotten odor in severe casesThin, gray-white, fishy odor
Cervical cell abnormality riskIncreased (moderate or severe AV)Not independently associated
Detected on standard BV panelOften noYes

What this means for you: a negative bacterial vaginosis test does not rule out AV. In one molecular study, women classified as having 'altered flora' on standard BV scoring sometimes tested AV-positive when checked with a specific AV-focused method. If your symptoms persist after BV treatment, AV is a leading possibility worth investigating directly.

Why a Single Reading May Not Be Enough

The vaginal microbiome shifts substantially across the menstrual cycle, with sexual activity, after antibiotic use, and during pregnancy. A single swab gives you a snapshot, not a trajectory. If your first test shows AV, a follow-up test 3 to 4 weeks after treatment is the most reliable way to confirm the infection actually cleared, since symptom improvement does not always equal microbiological cure.

In an RCT of 80 women with mixed AV and bacterial vaginosis, total bacterial counts dropped sharply right after treatment and rebounded slightly weeks later. Tracking your trend across baseline, post-treatment, and recurrence checkpoints gives you a much clearer picture than a one-time result. For anyone experiencing recurrent symptoms, retesting every 3 to 6 months until consistently normal is reasonable.

When Results Can Be Misleading

  • Recent intercourse or douching: semen, lubricants, and rinsing can temporarily change vaginal pH and bacterial composition. Most labs recommend abstaining for 48 hours before sampling.
  • Menstruation: blood in the sample distorts microscopy and bacterial counts. Wait until your period has ended before testing.
  • Recent antibiotic use: antibiotics taken in the prior 2 to 4 weeks can suppress the bacteria the test is trying to detect, masking AV temporarily or eliminating protective lactobacilli.
  • Relative vs absolute bacterial measurement: when labs report bacterial proportions rather than counts, a drop in total bacteria can falsely look like a rise in lactobacilli. Knowing which method your lab uses matters for interpreting follow-up results.

What to Do With an Out-of-Pattern Result

If your result shows moderate or severe AV, the next step is not just retesting. Pair the swab with culture or molecular identification of the specific bacteria present, since AV pathogens are often multidrug-resistant. This identifies which treatment will actually work for your particular case. If you are pregnant, share the result with your obstetric team promptly given the link with premature rupture of membranes and postpartum infection.

If you are getting recurrent or mixed infections, request testing for bacterial vaginosis, Candida species, and Trichomonas alongside AV, because mixed infections are common and one negative test does not exclude the others. Consider a gynecologist or sexual health specialist familiar with AV if your local provider treats every case as bacterial vaginosis by default.

What Moves This Biomarker

Evidence-backed interventions that affect your Aerobic Vaginitis level

Decrease
Intravaginal clindamycin cream
Clindamycin is the most commonly used first-line therapy for moderate to severe AV and is preferred over metronidazole in the IDSA/ASM 2024 guidelines. In a UK sexual health clinic series of 1,616 wet mounts, intravaginal clindamycin was used in about half of moderate to severe AV cases, with 43% reporting full symptom resolution. In an RCT of 80 women with mixed AV and bacterial vaginosis, clindamycin cream significantly improved Donders and Nugent scores, indicating real reduction in the AV pattern.
MedicationStrong Evidence
Decrease
Oral Lactobacillus probiotic (three-strain) added to standard antibiotics
In a randomized, double-blind, placebo-controlled trial in women with recurrent bacterial vaginosis and AV, adding an oral three-strain Lactobacillus probiotic to standard antibiotic therapy delayed AV relapse by up to 76%. The probiotic group also showed sustained reductions in vaginal pH, improved microscopy scores, and higher Lactobacillus counts. The regimen was taken twice daily for 10 days alongside antibiotics, then daily for 10 days perimenstrually during follow-up.
SupplementStrong Evidence
Decrease
Fufang Furong effervescent vaginal suppository
In an RCT of 80 women with mixed AV and bacterial vaginosis, this herbal suppository performed similarly to clindamycin cream on Donders and Nugent scores, and produced significantly greater Lactobacillus recovery by about 40 days after treatment. This suggests it may better restore protective flora alongside clearing infection.
MedicationStrong Evidence
Decrease
Microablative fractional CO2 laser therapy
In a prospective study of 53 postmenopausal women with elevated vaginal pH and atrophic smears, three monthly sessions of fractional CO2 laser shifted the vaginal environment toward health. Vaginal pH dropped from 5.5 to 4.7, and the share of women with detectable Lactobacillus rose from 30% to 79%. No clinical signs of AV, bacterial vaginosis, or candidiasis developed during follow-up.
MedicationModerate Evidence
Decrease
Eat a high-fiber diet
Higher dietary fiber intake was associated with lower bacterial vaginosis risk, with odds ratios of 0.22 to 0.49 across case-control (144 women) and cross-sectional (104 women) studies summarized in a review. Because AV shares a pattern of disrupted lactobacilli and inflammation with bacterial vaginosis, fiber may favor the lactobacillus-friendly environment that protects against both. Direct AV-specific dietary trials are not yet available.
DietModerate Evidence
Increase
Eat a high-glycemic-load diet (sugary, refined carb-heavy)
Higher dietary glycemic load was associated with increased bacterial vaginosis risk, with odds ratios of 1.04 to 4.01 across a case-control study (144 women) and a cohort study (1,735 women). Because AV and bacterial vaginosis share the underlying problem of disrupted lactobacilli, this dietary pattern likely works against the protective vaginal environment AV testing assesses. Direct AV evidence is not yet available.
DietModerate Evidence

Frequently Asked Questions

Panels containing Aerobic Vaginitis

Aerobic Vaginitis is included in these pre-built panels.

References

30 studies
  1. Oh K, Lee S, Lee MS, Lee MJ, Shim E, Hwang YH, Ha J, Yang YS, Hwang I, Park JSFrontiers in Cellular and Infection Microbiology2021
  2. Vieira-baptista P, Lima-silva J, Pinto C, Saldanha C, Beires J, Martinez-de-oliveira J, Donders GEuropean Journal of Clinical Microbiology & Infectious Diseases2016
  3. Aklilu a, Woldemariam M, Manilal a, Koira G, Alahmadi RM, Raman G, Idhayadhulla a, Yihune MScientific Reports2024
  4. Salinas a, Osorio V, Pacha-herrera D, Vivanco JS, Trueba AF, Machado aScientific Reports2020